Corona virus | China approves emergency use of two Govit-19 drugs NNDC | Technology

Chinese drug regulatory authority grants emergency use approval for two drugs based on monoclonal antibodies for treatment COVID-19 Adolescents and adults with mild and moderate symptoms, the official media reported today.

View: One year since the vaccine was launched in the world: how much progress has been made in Peru and what are the challenges?

Drugs known as BRII-196 and BRII-198, Tsinghua University, Shenzhen (Southern) People’s Hospital no. 3 and developed by Brii Biosciences, according to state-owned Xinhua.

This is, according to this media, the first treatment against Corona virus This type of approved China Under independent intellectual property.

Information released by the National Administration of Medical Products indicates that drugs are used in adolescents and adults in combination with mild to moderate symptoms and high risk factors leading to evolution to severe stages of the disease.

At the moment, this treatment is recommended for adolescents aged 12 to 17 who weigh more than 40 kg.

Medications use antibodies derived from transient patients COVID-19 They have demonstrated the ability to neutralize the virus in stages of previously developed clinical trials.

In late August, Biobiology announced that this treatment would reduce hospital admissions and deaths by up to 78%. COVID-19 Phase III clinical trials were conducted in the United States, Brazil, South Africa, Mexico, Argentina, and the Philippines.

In China, the third phase of testing was conducted in Guangzhou and Shenzhen (southern Guangzhou province) and Nanjing and Yangzhou (eastern Jiangsu province).

Chinese companies and organizations are developing two more drugs against the new corona virus.

State pharmaceutical company Sinoform – responsible for two vaccines against COVID-19 It is being used in many countries – exploring a treatment based on plasma of recovered patients whose clinical trials will begin soon in the United Arab Emirates.

Meanwhile, biotechnology company Kinder is working on the third formula, which is also in the testing phase.

China Since the outbreak began, it has accumulated 99,454 infections – 83 of which were reported this Thursday- and 4,636 deaths from Kovit-19, according to data from the National Health Commission.

The Asian country currently rejects living with the virus and maintains a “zero tolerance” policy, which uses strict border closures and strict control measures and movement controls.

Recommended video

You may also be interested in: